Global research hotspots on oncology–bibliometric analysis based on the ESI hot papers_Journal of Biomedical Engineering

Authors：

HAN Xuejiao ¹ , LI Xuemei ² , GONG Xiaoqing ³ ,  LI Baihong ⁴ , BAI Bei ⁵ ,  ZHANG Longhao ⁴ , PU Jian ⁴ , LI Yin ⁴ , ZHANG Mingming ⁶

1. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
2. Quality Management Department, Southwestern Hospital, Army Medical University, Chongqing 400038, P.R.China;
3. Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
4. Double First-class Construction Office, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
5. Dean’s Office/Department of Emergency Management, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
6. Chinese Evidence Based Med Ctr, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;

Corresponding author：

LI Baihong, Email: bhli1984@163.com; ZHANG Longhao, Email: zhanglonghao1990@hotmail.com

Keywords：

oncology; research hotspot; bibliometric analysis

DOI：

10.7507/1001-5515.202009083

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the increasing global burden of various cancer, an abundance of papers emerged every year in the research hotspots of oncology, covering a wide range of research types and topics. In order to facilitate interested readers to quickly grasp the frontier and hotspots of cancer research, it would be helpful to sort out and summarize the research topic in a timely manner. According to the classification of disciplines, we screened the Essential Science Indicators (ESI) hot papers released in 2019 for the ones in the oncology field, utilized methods such as bibliometrics, statistical description, hierarchical induction, analysis and interpretation to further reveal the context and characteristics of research in the field of oncology, summarized the latest progresses and future directions in the field, and provided information and hints for the trajectory of future research. A total of 549 papers were included, which were mainly from the field of clinical medicine; the country with the most publications was the United States, while China ranked the fourth in terms of contribution; the research institution with the highest number of published papers was University of Texas system; N Engl J Med published the most papers, with contribution also from highly influential journals in the field of oncology such as Lancet Oncol, J Clin Oncol, JAMA Oncol and Cancer Discov. Oncology remained the most popular research topic in the medical research and spanned a wide spectrum of sub-topics. In this study, we demonstrated and sorted out research frontiers in the field of oncology in 12 different research directions including the basic cancer research, cancer epidemiology, and various tumors types related to different systems and organs.

Citation： HAN Xuejiao, LI Xuemei, GONG Xiaoqing, LI Baihong, BAI Bei, ZHANG Longhao, PU Jian, LI Yin, ZHANG Mingming. Global research hotspots on oncology–bibliometric analysis based on the ESI hot papers. Journal of Biomedical Engineering, 2020, 37(6): 1012-1024. doi: 10.7507/1001-5515.202009083 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	World Health Organization. Global Health Observatory. Geneva: World Health Organization. 2018.
3.	宋伟. 医工结合康复训练器械的设计应用及其发展方向. 中国医疗器械信息, 2009, 15(01): 1-2, 13.
4.	Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res, 2017, 23(8): 1920-1928.
5.	Barroso-Sousa R, Barry W T, Garrido-Castro A C, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol, 2018, 4(2): 173-182.
6.	Wang D Y, Salem J E, Cohen J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol, 2018, 4(12): 1721-1728.
7.	Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol, 2019, 5(7): 1008-1019.
8.	Yuan Y, Haiying G, Zhuo L, et al. Long non-coding RNA LINC00339 facilitates the tumorigenesis of non-small cell lung cancer by sponging miR-145 through targeting FOXM1. Biomed Pharmacother, 2018, 105: 707-713.
9.	Beg M S, Brenner A J, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs, 2017, 35(2): 180-188.
10.	Liang G, Kan S, Zhu Y, et al. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomedicine, 2018, 13: 585-599.
11.	Hyman D M, Piha-Paul S A, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554(7691): 189-194.
12.	Ma Q, Wei R, Zhou B, et al. Antiangiogenic phenylpropanoid glycosides from Gynura cusimbua. Nat Prod Res, 2019, 33(4): 457-463.
13.	Laumont C M, Vincent K. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med, 2018, 10: 470.
14.	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
15.	Smith R A, Andrews K S, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, 2017, 67(2): 100-121.
16.	Islami F, Goding Sauer A, Miller K D, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin, 2018, 68(1): 31-54.
17.	Brown P D, Ballman K V, Cerhan J H, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC•3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 2017, 18(8): 1049-1060.
18.	Weller M, Butowski N, Tran D D, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol, 2017, 18(10): 1373-1385.
19.	Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA, 2017, 318(23): 2306-2316.
20.	Gao J, Li J, Geng W C, et al. Biomarker displacement activation: a general host-guest strategy for targeted phototheranostics in vivo. J Am Chem Soc, 2018, 140(14): 4945-4953.
21.	Bauml J, Seiwert T Y, Pfister D G, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol, 2017, 35(14): 1542-1549.
22.	Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, 2019, 393(10166): 51-60.
23.	Cohen E E W, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, 2019, 393(10167): 156-167.
24.	Ferris R L, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med, 2016, 375(19): 1856-1867.
25.	Long G V, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol, 2018, 19(5): 672-681.
26.	Puram S V, Tirosh I, Parikh A S, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell, 2017, 171(7): 1611-1624.
27.	Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol, 2018, 36(17): 1675-1684.
28.	Alley E W, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol, 2017, 18(5): 623-630.
29.	Zhong W Z, Wang Q, Mao W M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol, 2018, 19(1): 139-148.
30.	Garassino M C, Cho B C, Kim J H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol, 2018, 19(4): 521-536.
31.	Ratcliffe M J, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res, 2017, 23(14): 3585-3591.
32.	Sperduto P W, Yang T J, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol, 2017, 3(6): 827-831.
33.	Lee C K, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(2): 210-216.
34.	Giuliano A E, Ballman K V, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA, 2017, 318(10): 918-926.
35.	Sparano J A, Gray R J, Makower D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med, 2018, 379(2): 111-121.
36.	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med, 2017, 377(2): 122-131.
37.	Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA, 2017, 318(22): 2199-2210.
38.	Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol, 2018, 19(1): 40-50.
39.	de Boer M, van Leeuwen F E, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol, 2018, 4(3): 335-341.
40.	Bullman S, Pedamallu C S, Sicinska E, et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science, 2017, 358(6369): 1443-1448.
41.	Taieb J, Kourie H R, Emile J F, et al. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol, 2018, 4(7): e173695.
42.	Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 2018, 391(10135): 2128-2139.
43.	Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol, 2018, 29(4): 1016-1022.
44.	Venook A P, Niedzwiecki D, Lenz H J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA, 2017, 317(23): 2392-2401.
45.	Overman M J, Lonardi S, Wong K Y M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol, 2018, 36(8): 773-779.
46.	Tiriac H, Belleau P, Engle D D. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov, 2018, 8(9): 1112-1129.
47.	Balachandran V P, Łuksza M, Zhao J N, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551(7681): 512-516.
48.	Abou-Alfa G K, Meyer T, Cheng A L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med, 2018, 379(1): 54-63.
49.	Chen J, Li Y, Zheng Q, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett, 2017, 388: 208-219.
50.	Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol, 2017, 3(10): 1335-1342.
51.	Dejea C M, Fathi P, Craig J M. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science, 2018, 359(6375): 592-597.
52.	Møller P, Seppälä T T, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67(7): 1306-1316.
53.	Beer T M, Kwon E D, Drake C G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol, 2017, 35(1): 40-47.
54.	Smith M R, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med, 2018, 378(15): 1408-1418.
55.	Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol, 2018, 36(5): 446-453.
56.	Martin R M, Donovan J L, Turner E L, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA, 2018, 319(9): 883-895.
57.	Szmulewitz R Z, Peer C J, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol, 2018, 36(14): 1389-1395.
58.	de Bono J S, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. Eur Urol, 2018, 74(1): 37-45.
59.	Ku S Y, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 2017, 355(6320): 78-83.
60.	Miao D, Margolis C A. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359(6377): 801-806.
61.	Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med, 2018, 379(5): 417-427.
62.	Ledermann J A, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol, 2016, 17(11): 1579-1589.
63.	Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 2018, 379(26): 2495-2505.
64.	Swisher E M, Lin K K, Oza A M, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol, 2017, 18(1): 75-87.
65.	Coleman R L, Oza A M, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 390(10106): 1949-1961.
66.	Tawbi H A, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol, 2017, 18(11): 1493-1501.
67.	Boevé L M S, Hulshof M, Vis A N, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol, 2019, 75(3): 410-418.
68.	Davids M S, Roberts A W, Seymour J F, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol, 2017, 35(8): 826-833.
69.	André M P E, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 2017, 35(16): 1786-1794.
70.	DiNardo C D, Pratz K W, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol, 2018, 19(2): 216-228.
71.	Seymour J F, Kipps T J, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med, 2018, 378(12): 1107-1120.
72.	Chen R, Zinzani P L, Fanale M A, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol, 2017, 35(19): 2125-2132.
73.	Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med, 2018, 378(13): 1189-1199.
74.	Abelson S, Collord G, Ng S W K, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559(7714): 400-404.
75.	Brudno J N, Maric I, Hartman S D, et al. T cells genetically modified to express an anti-b-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol, 2018, 36(22): 2267-2280.
76.	Menzies A M, Johnson D B, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol, 2017, 28(2): 368-376.
77.	Schadendorf D, Wolchok J D, Hodi F S, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol, 2017, 35(34): 3807-3814.
78.	Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 2018, 36(17): 1658-1667.
79.	Dummer R, Ascierto P A, Gogas H J, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5): 603-615.
80.	Schachter J, Ribas A, Long G V, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 2017, 390(10105): 1853-1862.
81.	Migden M R, Rischin D, Schmults C D, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med, 2018, 379(4): 341-351.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. World Health Organization. Global Health Observatory. Geneva: World Health Organization. 2018.
3. 宋伟. 医工结合康复训练器械的设计应用及其发展方向. 中国医疗器械信息, 2009, 15(01): 1-2, 13.
4. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res, 2017, 23(8): 1920-1928.
5. Barroso-Sousa R, Barry W T, Garrido-Castro A C, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol, 2018, 4(2): 173-182.
6. Wang D Y, Salem J E, Cohen J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol, 2018, 4(12): 1721-1728.
7. Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol, 2019, 5(7): 1008-1019.
8. Yuan Y, Haiying G, Zhuo L, et al. Long non-coding RNA LINC00339 facilitates the tumorigenesis of non-small cell lung cancer by sponging miR-145 through targeting FOXM1. Biomed Pharmacother, 2018, 105: 707-713.
9. Beg M S, Brenner A J, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs, 2017, 35(2): 180-188.
10. Liang G, Kan S, Zhu Y, et al. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomedicine, 2018, 13: 585-599.
11. Hyman D M, Piha-Paul S A, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554(7691): 189-194.
12. Ma Q, Wei R, Zhou B, et al. Antiangiogenic phenylpropanoid glycosides from Gynura cusimbua. Nat Prod Res, 2019, 33(4): 457-463.
13. Laumont C M, Vincent K. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med, 2018, 10: 470.
14. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
15. Smith R A, Andrews K S, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, 2017, 67(2): 100-121.
16. Islami F, Goding Sauer A, Miller K D, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin, 2018, 68(1): 31-54.
17. Brown P D, Ballman K V, Cerhan J H, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC•3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 2017, 18(8): 1049-1060.
18. Weller M, Butowski N, Tran D D, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol, 2017, 18(10): 1373-1385.
19. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA, 2017, 318(23): 2306-2316.
20. Gao J, Li J, Geng W C, et al. Biomarker displacement activation: a general host-guest strategy for targeted phototheranostics in vivo. J Am Chem Soc, 2018, 140(14): 4945-4953.
21. Bauml J, Seiwert T Y, Pfister D G, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol, 2017, 35(14): 1542-1549.
22. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, 2019, 393(10166): 51-60.
23. Cohen E E W, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, 2019, 393(10167): 156-167.
24. Ferris R L, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med, 2016, 375(19): 1856-1867.
25. Long G V, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol, 2018, 19(5): 672-681.
26. Puram S V, Tirosh I, Parikh A S, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell, 2017, 171(7): 1611-1624.
27. Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol, 2018, 36(17): 1675-1684.
28. Alley E W, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol, 2017, 18(5): 623-630.
29. Zhong W Z, Wang Q, Mao W M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol, 2018, 19(1): 139-148.
30. Garassino M C, Cho B C, Kim J H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol, 2018, 19(4): 521-536.
31. Ratcliffe M J, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res, 2017, 23(14): 3585-3591.
32. Sperduto P W, Yang T J, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol, 2017, 3(6): 827-831.
33. Lee C K, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(2): 210-216.
34. Giuliano A E, Ballman K V, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA, 2017, 318(10): 918-926.
35. Sparano J A, Gray R J, Makower D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med, 2018, 379(2): 111-121.
36. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med, 2017, 377(2): 122-131.
37. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA, 2017, 318(22): 2199-2210.
38. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol, 2018, 19(1): 40-50.
39. de Boer M, van Leeuwen F E, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol, 2018, 4(3): 335-341.
40. Bullman S, Pedamallu C S, Sicinska E, et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science, 2017, 358(6369): 1443-1448.
41. Taieb J, Kourie H R, Emile J F, et al. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol, 2018, 4(7): e173695.
42. Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 2018, 391(10135): 2128-2139.
43. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol, 2018, 29(4): 1016-1022.
44. Venook A P, Niedzwiecki D, Lenz H J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA, 2017, 317(23): 2392-2401.
45. Overman M J, Lonardi S, Wong K Y M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol, 2018, 36(8): 773-779.
46. Tiriac H, Belleau P, Engle D D. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov, 2018, 8(9): 1112-1129.
47. Balachandran V P, Łuksza M, Zhao J N, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551(7681): 512-516.
48. Abou-Alfa G K, Meyer T, Cheng A L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med, 2018, 379(1): 54-63.
49. Chen J, Li Y, Zheng Q, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett, 2017, 388: 208-219.
50. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol, 2017, 3(10): 1335-1342.
51. Dejea C M, Fathi P, Craig J M. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science, 2018, 359(6375): 592-597.
52. Møller P, Seppälä T T, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67(7): 1306-1316.
53. Beer T M, Kwon E D, Drake C G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol, 2017, 35(1): 40-47.
54. Smith M R, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med, 2018, 378(15): 1408-1418.
55. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol, 2018, 36(5): 446-453.
56. Martin R M, Donovan J L, Turner E L, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA, 2018, 319(9): 883-895.
57. Szmulewitz R Z, Peer C J, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol, 2018, 36(14): 1389-1395.
58. de Bono J S, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. Eur Urol, 2018, 74(1): 37-45.
59. Ku S Y, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 2017, 355(6320): 78-83.
60. Miao D, Margolis C A. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359(6377): 801-806.
61. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med, 2018, 379(5): 417-427.
62. Ledermann J A, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol, 2016, 17(11): 1579-1589.
63. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 2018, 379(26): 2495-2505.
64. Swisher E M, Lin K K, Oza A M, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol, 2017, 18(1): 75-87.
65. Coleman R L, Oza A M, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 390(10106): 1949-1961.
66. Tawbi H A, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol, 2017, 18(11): 1493-1501.
67. Boevé L M S, Hulshof M, Vis A N, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol, 2019, 75(3): 410-418.
68. Davids M S, Roberts A W, Seymour J F, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol, 2017, 35(8): 826-833.
69. André M P E, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 2017, 35(16): 1786-1794.
70. DiNardo C D, Pratz K W, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol, 2018, 19(2): 216-228.
71. Seymour J F, Kipps T J, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med, 2018, 378(12): 1107-1120.
72. Chen R, Zinzani P L, Fanale M A, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol, 2017, 35(19): 2125-2132.
73. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med, 2018, 378(13): 1189-1199.
74. Abelson S, Collord G, Ng S W K, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559(7714): 400-404.
75. Brudno J N, Maric I, Hartman S D, et al. T cells genetically modified to express an anti-b-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol, 2018, 36(22): 2267-2280.
76. Menzies A M, Johnson D B, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol, 2017, 28(2): 368-376.
77. Schadendorf D, Wolchok J D, Hodi F S, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol, 2017, 35(34): 3807-3814.
78. Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 2018, 36(17): 1658-1667.
79. Dummer R, Ascierto P A, Gogas H J, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5): 603-615.
80. Schachter J, Ribas A, Long G V, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 2017, 390(10105): 1853-1862.
81. Migden M R, Rischin D, Schmults C D, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med, 2018, 379(4): 341-351.

Journal of Biomedical Engineering

Global research hotspots on oncology–bibliometric analysis based on the ESI hot papers

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content